Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Active, not recruiting · Phase 1, Phase 2 · NCT04956640
Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
At a glance
- Research payments reported, 2025
- $5.6M
- U.S. investigators named
- 24
- Sites paid
- 24
- Planned or actual enrollment
- 540
About the trial
- Sponsor
- Eli Lilly and Company (with Merck Sharp & Dohme LLC)
- Tested
- LY3537982 (drug), Pembrolizumab (drug), Cetuximab (drug), Pemetrexed (drug), Cisplatin (drug), Carboplatin (drug)
- Dates
- Started 2021-07-19; completion 2027-04
- Results posted
- Not yet
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
From ClinicalTrials.gov, last updated 2026-05-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5.6M in research payments for this study in 2025 (25 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Maya Khalil Hematology & Oncology · Birmingham, AL
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- So Yeon Kim, MD Medical Oncology · North Haven, CT
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Mark A. Socinski, MD Hematology & Oncology · Orlando, FL
- Natraj R. Ammakkanavar, M.D Medical Oncology · Indianapolis, IN
- Gregory A. Durm, MD Hematology & Oncology · Indianapolis, IN
- Victor T. Lin, MD, PHD Hematology & Oncology · Baton Rouge, LA
- Rebecca S. Heist, MD MPH Internal Medicine · Boston, MA
- Shetal A. Patel, M.D., PH.D. Medical Oncology · Chapel Hill, NC
- Garrett B. Sherwood, M.D. Medical Oncology · Winston Salem, NC
- Konstantin H. Dragnev, MD Hematology & Oncology · Lebanon, NH
- Yonina R. Murciano-goroff, MD, DPHIL Internal Medicine · New York, NY
- Joshua K. Sabari, M.D. Hematology & Oncology · New York, NY
- Joseph N. Bodor, MD, PHD Medical Oncology · Philadelphia, PA
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- Cathy Eng, M.D. Medical Oncology · Nashville, TN
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Justin A. Call, M.D. Medical Oncology · West Jordan, UT
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Raymond C. Wadlow, MD Hematology & Oncology · Fairfax, VA
- Dustin A. Deming, M.D. Medical Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $628,331
- Novant Health Cancer Institute - Forsyth $486,245
- South Texas Accelerated Research Therapeutics LLC $393,231
- Board of Regents of the Univ of Wisconsin Systm $376,772
- New York University $338,933
- Community Hospital East, IN $333,873
- Fox Chase Cancer Center $332,297
- Univ of Pittsburgh Cancer Institute Cancer Srvcs $322,785
- Inova Loudoun Hospital, VA $295,048
- Yale University $284,975
- Uci Health-Orange, CA $236,407
- Sarah Cannon Research Institute LLC $236,153
- University of Alabama Hospital, AL $221,537
- Fairfax-Northern Virginia $196,199
- Adventhealth Orlando, FL $196,103
- Usc School of Medicine $128,278
- University of North Carolina at Chapel Hill $127,614
- Vanderbilt University Medical Center, TN $99,736
- Mary Bird Perkins Cancer Center $95,862
- Dartmouth Hitchcock Clinic $89,723
- Indiana University $78,383
- Dana Farber PArtners Cancer Care Inc $62,849
- Start Mountain Region LLC $41,854
- Florida Cancer Specialists $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.